<DOC>
	<DOCNO>NCT01867307</DOCNO>
	<brief_summary>Single center , 14-day , open-label trial examine effect 25 mg q.d . empagliflozin kinetics renal glucose reabsorption patient diagnose type 2 diabetes mellitus healthy control</brief_summary>
	<brief_title>Effect Empagliflozin Kinetics Renal Glucose Reabsorption Patients With Type II Diabetes Healthy Controls</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : 1 . T2DM patient healthy control age =18 &lt; 70 Visit 1 . 2 . Patients diagnose T2DM accord American Diabetes Association criterion prior inform consent drugna√Øve 3 . T2DM patient stable dose allow concomitant medication ( determined investigator ) 30 day prior enter study . 4 . T2DM patient HbA1c &gt; 7 &lt; 10.0 % ( &gt; 53 mmol/mol &lt; 86 mmol/mol ) Visit Exclusion criterion : 1 . Patients type 1 diabetes mellitus . 2 . Patients uncontrolled hyperglycemia fast plasma glucose level great 240 mg/dl overnight fast . 3 . Patients history clinically significant heart disease ( New York Heart Classification great class 3 ; nonspecific STT wave change ECG ) , peripheral vascular disease ( history claudication ) , pulmonary disease determine investigator . 4 . Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>